Research article · 19 Aug 2025
Conference abstractPublished 16 Apr 2018
The importance of implementing clinical design support system while using electronic prescriptions
King Salman Armed Forces Hospital-North Western Region, KSA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Seventy years since its discovery and 59 since its commercial introduction in 1954, warfarin remains the most widely used oral anticoagulant. However, the FDA approval of new anticoagulants Dabigatran (October 2010) and Rivaroxaban (November 2011) are changing the landscape of oral anticoagulant therapy. Both of these new agents are indicated for stroke and systemic embolism prophylaxis in patients with nonvalvular atrial fibrillation (AF). Rivaroxaban also has additional indications for treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). The purpose of this study is to mitigate the bleeding risks associated with oral anticoagulants; reversal strategies include withholding the anticoagulant, vitamin K (warfarin only), and/or factor replacement (FFP, PCC, or rFVIIa). The choice of reversal strategy is largely guided by the pharmacology of the oral anticoagulant and the urgency of the situation. The pharmacist plays an important role as additional prevention layer for any prescribing error by catching medication errors mainly as a result of lack of knowledge of the prescribers. Electronic prescribing system is a worthy system to be used to reduce the medication prescribing errors. However, clinical pharmacist should be involved in the drug choice because he/she is an integral part to ensure patient safety and improve the prescribing service. Recent Publications 1. Mohamed H Ragab, Mohammed Y Al-Hindi and Meshari M Alrayees (2016) Neonatal parenteral nutrition: Review of the pharmacist role as a prescriber. Saudi Pharm J.; 24(4): 429âÂ?Â?440. 2. Alatawi Y M, Kavookjian J, Ekong G, Alrayees M M (2016) The association between health beliefs and medication adherence among patients with type-2 diabetes. Res Social Adm Pharm.; 12(6): 914-925.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Drug Designing: Open Access.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalDrug Designing: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Meshari Alrayees”

